As reported by Law360, on April 8, 2022, U.S. District Judge Charles R. Breyer of the Northern District of California issued a ruling that Teva Pharmaceuticals, Allergan, Anda Inc. and other major pharmaceutical companies and distributors allegedly responsible for the manufacturing, transmission, and sale of dangerous, highly addictive and often lethal prescription opioids such as Oxycontin and fentanyl,
City of Nashville Mayor John Cooper has announced that the city of Nashville will receive $23 million to recoup taxpayer funds allocated to emergency government responses to the opioid epidemic from 2017 through the present. The news comes in the wake of an historic $26 billion nationwide settlement with American opioid manufacturers and distributors reached
Over 90% of litigating local governments have confirmed participation in the global settlements approved today by the “Big Three” drug distributors AmerisourceBergen, Cardinal Health, and McKesson, along with opioid manufacturer Johnson & Johnson Washington, D.C. (February 25, 2022) – Today, the National Prescription Opiate Litigation Plaintiffs’ Executive Committee confirmed participation of over 90% of litigating
As reported by The New York Times (subscription) and multiple other outlets, Native American tribes have reached a $590 million proposed settlement agreement with Johnson & Johnson and three of the country’s largest opioid distributors to resolve claims over the companies’ alleged role in fueling the massive opioid addiction crisis responsible
As reported by Law360, in a first-of-its-kind ruling, a federal jury has found pharmacy giants CVS, Walgreens and Walmart liable for fueling the opioid addiction crisis in two Ohio counties. After a six-week trial and one week of deliberations, jurors concluded that the sale and distribution of huge amounts of prescription opioids by the pharmacy
Lieff Cabraser partner Mark P. Chalos spoke as a featured panelist at the Georgetown Law School virtual summit “Opioid Litigation Summit: Maximizing the Impact of Settlements to Address the Opioid Epidemic.” Mark participated in “State of the Settlements, Bellwethers, and Settlement Design Innovations.”
The Am Law Litigation Daily has named Lieff Cabraser partner Elizabeth Cabraser and her colleagues on the negotiating team of plaintiffs’ lawyers behind the recently revamped $26 billion proposed opioid settlement as its Litigators of the Week for their role in getting the deal with Johnson & Johnson and three opioid
Patients across the U.S. have been reporting hidden and dangerous side effects in the 2012-era Japanese appetite suppressant Belviq (Lorcaserin). As obesity remains a public health crisis in the U.S., many Americans struggle daily in an effort to lose weight. From 2012 onward, Belviq was introduced in the United States promising meaningful weight loss, and
FDA mandates halt to distribution of ranitidine (Zantac) due to potentially carcinogenic contamination After previously warning consumers and doctors last September that it had found measurable amounts of the carcinogen NDMA (N-notrisodimethylamine) in samples of the widely-used heartburn medication Zantac, the U.S. Food and Drug Administration has now ordered manufacturers to immediately stop distributing all
On February 5, 2020, Judge Andrew Y.S. Cheng of the Superior Court for the County of San Francisco issued an order appointing Lieff Cabraser partner Sarah R. London to the Plaintiffs’ Executive Committee in the Gilead HIV Drug Kidney & Bone Injuries Litigation. Sarah will lead the litigation on behalf of patients across California who allege they suffered kidney